News Tag: 2022 newsletters
Assessing the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer (NRG-CC010)
Read More
NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer
Read More
NRG-BR007 (“DEBRA”): A Phase III Clinical Trial Evaluating the De-escalation of Breast Radiation for a More Conservative Treatment of Patients With Low-Risk, Hormone-Sensitive, Node-Negative Breast Cancer
Read More
In Memoriam: James Lloyd Hoehn, MD, FACS
Read More
Protocol Committee Support (PSC) Column: No Surprises Billing Act 2022
Read More
NRG Health Equity Fellowship Call for Applications
Read More
Comparing the Addition of Radiation before or After Surgery for Patients with Brain Metastases (NRG-BN012)
Read More
Comparing Every Three Week Versus Weekly Cisplatin with Radiotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)
Read More
NRG-GU011 (“NRG PROMETHEAN”) study of SABR with or without relugolix for PET-recurrent oligometastatic prostate cancer
Read More
NRG-GU009 ( “PREDICT-RT”) Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation
Read More